- HOME
- 홈페이지 이용안내
논문 기본정보
Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses
논문 개요
| 기관명 | NDSL |
|---|---|
| 저널명 | BMB reports |
| ISSN | 1976-6696,1976-670x |
| ISBN |
논문저자 및 소속기관 정보
| 저자(한글) | Jung, Byeongjin,Kang, Hyejin,Lee, Wonhwa,Noh, Hyun Jin,Kim, You-Sun,Han, Min-Su,Baek, Moon-Chang,Kim, Jaehong,Bae, Jong-Sup |
|---|---|
| 저자(영문) | |
| 소속기관 | |
| 소속기관(영문) | |
| 출판인 | |
| 간행물 번호 | |
| 발행연도 | 2016-01-01 |
| 초록 | A nucleosomal protein, high mobility group box 1 (HMGB1) is known to be a late mediator of sepsis. Dabrafenib is a B-Raf inhibitor and initially used for the treatment of metastatic melanoma therapy. Inhibition of HMGB1 and renewal of vascular integrity is appearing as an engaging therapeutic strategy in the administration of severe sepsis or septic shock. Here, we examined the effects of dabrafenib (DAB) on the modulation of HMGB1-mediated septic responses. DAB inhibited the release of HMGB1 and downregulated HMGB1-dependent inflammatory responses by enhancing the expressions of cell adhesion molecules (CAMs) in human endothelial cells. In addition, treatment with DAB inhibited the HMGB1 secretion by CLP and sepsis-related mortality and pulmonary injury. This study demonstrated that DAB could be alternative therapeutic options for sepsis or septic shock via the inhibition of the HMGB1 signaling pathway. |
| 원문URL | http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=JAKO201616960461208 |
| 첨부파일 |
추가정보
| 과학기술표준분류 | |
|---|---|
| ICT 기술분류 | |
| DDC 분류 | |
| 주제어 (키워드) | Barrier integrity,Dabrafenib,HMGB1,Sepsis |